Zydus Cadila has received final approval from US Food and Drug Administration (USFDA) to market Acyclovir Sodium Injection, 500 mg (base)/10 mL (50 mg (base)/ml) and 1,000 mg (base)/20mL (50 mg (base)/mL) single-dose vials (US RLD-Zovirax for injection). It will be manufactured at the group's formulations manufacturing facility at Moraiya in Ahmedabad.
Acyclovir is an antiviral drug. It slows the growth and spread of the herpes virus in the body. Acyclovir injection is used to treat severe infections caused by herpes viruses. The group now has 216 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1860.40 |
| Dr. Reddys Lab | 1275.80 |
| Cipla | 1304.20 |
| Zydus Lifesciences | 936.75 |
| Lupin | 2268.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: